Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae268Source: DataRank Database

Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial is a research paper published in JNCI Journal of the National Cancer Institute (2024). On theSindex it has a DataRank of 0.394. It has been cited 5 times, with 3 citing works in its 1-hop citation network.

N/A

0.394DataRank · unranked

Scored on demand from live citation data

Open Access5 citations · 3 citing works in its network

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (21 grants)Impact (FWCI 0.88)OA: hybridTopics (62)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 68%Citation Network 32%

Base Score Contribution

0.269

From this paper's citation signal

Citation Network Contribution

0.125

From 2 citing papers with measurable signal

Learn more about DataRank methodology →

Top 3 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 3 citers.

RE: Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial
JNCI Journal of the National Cancer Institute20251 citations5 referencesContributes 0.139
iS2C2: a cointelligent platform for mechanistic discovery of disease cellular crosstalk
Signal Transduction and Targeted Therapy20261 citations85 referencesContributes 0.008
In silico anticancer, antioxidant and anti-inflammatory study on GC–MS-based profiling of chloroform and hexane extracts of Erigeron multiradiatus
In Silico Pharmacology20260 citations43 referencesContributes 0.000

Authors (13)

Huma Dar ORCID,Anna Nordenskjöld ORCID,Gizeh Pérez‐Tenorio,Nicholas P. Tobin ORCID,Christina Yau ORCID

Live enrichment

PubMed:39656627 PMC:PMC12058260 OpenAlex:https://openalex.org/W4405233415

Vetenskapsrådet

Grant: 2020-02466

Vetenskapsrådet

Grant: 2023-03009

Swedish Research Council for Health, Working life and Welfare

Grant: 2019-00477

ALF medicine

Grant: FoUI-974882

Swedish Cancer Society

Grant: 222081

Swedish Cancer Society

Grant: 220552SIA

Swedish Cancer Society

Grant: 222216

Swedish Cancer Society

Grant: 200802

Cancerföreningen i Stockholm

Grant: 221233

Cancerföreningen i Stockholm

Grant: 201212

Cancerföreningen i Stockholm

Grant: 181093

Cancerföreningen i Stockholm

Grant: 224112

King Gustav V Jubilee Clinical Research Foundation

Grant: 2021-356

California Breast Cancer Research Program

Grant: 180B-0065

National Institutes of Health

Grant: U01-CA196406

National Institutes of Health

Grant: 5U01CA196406-04

Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancers

Swedish Research Council for Health, Working Life and Welfare

Grant: unidentified

unidentified

Stiftelsen Gösta Miltons donationsfond

Stockholm Cancer Society

Swedish Research Council

Gösta Milton Donation Fund

FWCI

0.88

Citation Percentile

0.7%

Citation Trend

2025

2026

hybridLicense: cc-by-nc

journalhttps://academic.oup.com/jnci/advance-article-pdf/doi/10.1093/jnci/djae268/60936643/djae268.pdf

publisherhttps://academic.oup.com/jnci/advance-article-pdf/doi/10.1093/jnci/djae268/60936643/djae268.pdf

publisherhttps://academic.oup.com/jnci/article-pdf/117/5/868/60936643/djae268.pdf

journalhttps://doi.org/10.1093/jnci/djae268

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39656627

Fields of Study

Breast Cancer Treatment StudiesEstrogen and related hormone effectsBRCA gene mutations in cancer03 medical and health sciences0302 clinical medicine

MeSH Terms

AdultAgedBreast NeoplasmsFemaleFollow-Up StudiesHumansMenopauseMiddle AgedReceptors, EstrogenReceptors, ProgesteroneSwedenTamoxifenBiomarkers, TumorProportional Hazards ModelsChemotherapy, AdjuvantPremenopausePostmenopauseReceptor, ErbB-2Erb-b2 Receptor Tyrosine KinasesAntineoplastic Agents, HormonalKi-67 AntigenKaplan-Meier Estimate

Keywords

TamoxifenMedicineHazard ratioBreast cancerInternal medicineOncologyProportional hazards modelConfidence intervalAdjuvant therapyEstrogen receptorGynecologyRandomized controlled trialCancerAdultCancer och onkologiAntineoplastic Agents, HormonalBreast NeoplasmsKaplan-Meier EstimateMiddle AgedErb-b2 Receptor Tyrosine KinasesArticlePostmenopauseKi-67 AntigenReceptors, EstrogenPremenopauseChemotherapy, AdjuvantCancer and OncologyBiomarkers, TumorHumansFemaleMenopauseReceptors, ProgesteroneProportional Hazards ModelsFollow-Up StudiesAged

Sustainable Development Goals

SDG 0: Good health and well-being